Scientific Depth, Reliability, Trust

Our API development capabilities are built on strong engineering expertise and a solid scientific foundation that enable the management of complex chemical syntheses and multi-step processes.

Our API R&D activities are carried out in line with product development objectives for both domestic and regulated markets, following a vertically integrated approach.

In 1970, DEVA achieved Turkey’s first pharmaceutical API production with tetracycline and oxytetracycline. By continuing its investments in this field, the company has become a leading manufacturer of pharmaceutical active ingredients.

Through this approach, we manage product quality from the earliest stages of the active ingredient and support long-term reliability and continuity across the supply chain.

This integrated structure, spanning from API synthesis to the finished product, enables us to deliver reliable and sustainable solutions.

One of DEVARGE’s key strengths is the ability to effectively and reliably translate scientific outcomes into manufacturing.

This process, where scientific knowledge moves from the laboratory environment to industrial production, is managed with an integrated approach covering formulation development, pilot production, scale-up and quality control.

Thanks to this capability, research outcomes do not remain at the laboratory level. By ensuring quality, continuity and regulatory compliance, they are transformed into scalable solutions and real healthcare products.

We build comprehensive capabilities in the development of biotechnological medicines and biosimilar products.

Our activities include cell line development, bioprocess optimization, analytical characterization and formulation studies, all conducted in accordance with international regulatory expectations.

Through strategic investments in this field, we expand our biosimilar portfolio and support patients’ access to advanced treatment options.